細胞名稱

人結直腸癌細胞SW837

貨物編碼

BFN681361

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   2類

培養體系

DMEM高糖（HYCLONE SH30022.01)+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人結直腸癌細胞SW837取自53歲男性供體，貼壁培養。

注釋

Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Part of: TCGA-110-CL cell line panel.

From: Scott and White Clinic; Temple; USA.

Doubling time: 169 hours, at 5th passage (PubMed=1000501).

Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger).

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: miRNA expression profiling.

Omics: N-glycan profiling.

Omics: O-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Rectum.

基因突變

APC p.Arg1450Ter (c.4348C>T) (ClinVar=VCV000194585) (PubMed=24755471).

FBXW7 p.Leu403fs*34 (c.1208_1209insT) (PubMed=24755471).

Heterozygous for KRAS p.Gly12Cys (c.34G>T) (ClinVar=VCV000012578) (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746).

Hemizygous for TP53 p.Arg248Trp (c.742C>T) (ClinVar=VCV000012347) (PubMed=7651727; PubMed=9715273; PubMed=16418264; PubMed=24755471; PubMed=28683746).

HLA信息

/

STR信息

Amelogenin X

CSF1PO 10

D3S1358 18

D5S818 12

D7S820 9,12

D8S1179 8,14

D13S317 13

D16S539 12

D18S51 17

D21S11 28,31.2

FGA 25

Penta D 9,11

Penta E 11,12

TH01 9.3

TPOX 8,9

vWA 15,16

參考文獻

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

 Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

 Differential effector engagement by oncogenic KRAS.

 Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

 An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

 Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

 Next-generation characterization of the Cancer Cell Line Encyclopedia.

 Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

 Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

 Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

 Nat. Commun. 10:3574-3574(2019)